An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Nivolumab (Primary) ; SX 682 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 07 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 07 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 08 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jan 2024.